- Home
- CDIO vs PMCB Comparison
CDIO vs PMCB Comparison
Compare CDIO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- PMCB
- Stock Information
- Founded
- CDIO 2017
- PMCB 1996
- Country
- CDIO United States
- PMCB United States
- Employees
- CDIO N/A
- PMCB N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDIO Health Care
- PMCB Health Care
- Exchange
- CDIO Nasdaq
- PMCB Nasdaq
- Market Cap
- CDIO 7.0M
- PMCB 7.1M
- IPO Year
- CDIO N/A
- PMCB N/A
- Fundamental
- Price
- CDIO $4.77
- PMCB $1.02
- Analyst Decision
- CDIO Buy
- PMCB
- Analyst Count
- CDIO 1
- PMCB 0
- Target Price
- CDIO $60.00
- PMCB N/A
- AVG Volume (30 Days)
- CDIO 102.5K
- PMCB 9.7K
- Earning Date
- CDIO 05-15-2025
- PMCB 03-17-2025
- Dividend Yield
- CDIO N/A
- PMCB N/A
- EPS Growth
- CDIO N/A
- PMCB N/A
- EPS
- CDIO N/A
- PMCB 1.29
- Revenue
- CDIO $19,902.00
- PMCB N/A
- Revenue This Year
- CDIO $1,434.82
- PMCB N/A
- Revenue Next Year
- CDIO $4,661.91
- PMCB N/A
- P/E Ratio
- CDIO N/A
- PMCB $0.86
- Revenue Growth
- CDIO N/A
- PMCB N/A
- 52 Week Low
- CDIO $3.40
- PMCB $1.00
- 52 Week High
- CDIO $53.10
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- CDIO 39.92
- PMCB 41.38
- Support Level
- CDIO $3.88
- PMCB $1.05
- Resistance Level
- CDIO $5.20
- PMCB $1.14
- Average True Range (ATR)
- CDIO 0.48
- PMCB 0.07
- MACD
- CDIO 0.32
- PMCB 0.01
- Stochastic Oscillator
- CDIO 68.25
- PMCB 13.33
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.